GlobeNewswire·Mar 3, 2026, 4:05 PM ET

Oculis Reports Q4 and Full Year 2025 Financial Results and Provides Company Update

OCS

Oculis Holding AG reported cash, cash equivalents, & short-term investments of $268.7 million as of December 31, 2025, providing a cash runway into 2029.
Privosegtor received FDA Breakthrough Therapy designation for optic neuritis based on Phase 2 ACUITY results, enabling the launch of the global PIONEER registrational program targeting a U.S. market opportunity exceeding $7 billion.
Phase 3 DIAMOND trials for OCS-01 eye drops in diabetic macular edema have enrolled over 800 patients, with topline results expected in Q2 2026 & an NDA submission planned for Q4 2026 if positive.
The PREDICT-1 registrational trial for Licaminlimab in dry eye disease initiated, utilizing a genotype-based precision medicine approach with topline results expected in Q4 2026.
Oculis announced three major 2026 milestones: DIAMOND-1 & DIAMOND-2 readouts for OCS-01, PREDICT-1 results for Licaminlimab, & the commencement of three PIONEER trials for Privosegtor.
Year-to-date net loss for 2025 was $119.1 million (CHF 99.0 million), primarily driven by increased R&D expenses from Phase 3 trials, personnel costs, & foreign exchange revaluation losses.
Cash position increased from $109.0 million in December 2024 to $268.7 million in December 2025 due to equity financings totaling $210.0 million closed in February & November 2025.
R&D expenses for the quarter ended December 31, 2025, were $16.6 million, while general & administrative expenses were $9.7 million, both reflecting increases from 2024 due to clinical advancements & operational scaling.